Agenda
*All times are in EST
Sep
Fri 29
Welcome reception
Sep
Sat 30
Introduction & Meeting Objectives
John Gribben
Session 1: T-cell lymphoma
Chairs: Laurence de Leval & Francine Foss
- Genomic profiling for clinical decision making in TCL: Laurence de Leval
- Translational discovery in PTCL: Giorgio Inghirami
- 5-azacitidine in follicular helper T-cell lymphomas: François Lemonnier
- Therapeutic options for the treatment of PTCLs: Francine Foss
- Targeting signaling pathways in T-cell lymphoma: Steven Horwitz
Panel Discussion
Break
Session 2: Evolving frontline immune-chemotherapy for MCL and the impact on survival outcomes
Chairs: Stephen Ansell & Elaine Jaffa
- Biological characteristics of high-risk MCL: Eric Hsi
- Significance of the TRIANGLE trial for MCL: Marek Trněný
- Future role of ASCT in MCL: John Kuruvilla
- Do you need to treat young and old MCL patients differently? Stephen Ansell
- Novel agents for relapsed MCL: Yucai Wang
- ViPOR regimen in MCL: Wyndham Wilson
Panel Discussion: Remaining gaps and perspectives
Session 3: Keynote address
Chair & Introduction: Andreas Rosenwald
- Emerging role of super-enhancer hypermutation deregulating gene expression
in DLBCL – pathogenetic and therapeutic implications: Riccardo Dalla-Favera
Panel Discussion
Lunch
Session 4: New pathogenetic mechanisms and therapeutic targets in DLBCL
Chairs: Riccardo Dalla-Favera & Ash Alizadeh
- Molecular pathogenesis of germinal center-derived B-cell lymphomas: Laura Pasqualucci
- Genomic alterations in DLBCL – new relevant pathways and potential therapeutic targets:
Ken Young - Cell-free DNA – mutations for MRD monitoring & epigenetics/fragmentomics for disease detection in various lymphomas: Ash Alizadeh
Panel Discussion
Break
Session 4: Novel Therapies Part 1
Chairs: John Gribben & Laurie Sehn
- Novel drug development: an industry perspective; Simon Rule
Industry Panel Discussion
Antibody-drug conjugates:
- POLARIX – Polatuzumab vedotin: Laurie Sehn
- Zilovertamab: Sven De Vos
- Loncastuximab tesirine: Paolo Caimi
- Camidanlumab: Andrew Davies
- Brentuximab vedotin: Stephen Ansell
- Emerging ADCs with novel targets: Juan Pablo Alderuccio
Menin inhibitors
- BMF-219: Paolo Caimi
Panel Discussion
Day 1 summary
Oct
Sun 01
Session 6: Expanding the CAR platform for NHL
Chairs: David Maloney & Jason Westin
- Tisa-cel; Stephen Schuster
- Axi-cel; Sattva Neelapu
- Liso-cel; David Maloney
- C-CAR066 & C-CAR039; John Gerecitano
- Expanding to T cell lymphomas; LaQuisa Hill
- CB-010: CD19-directed, PD-1 KO, AlloCAR for R/R B-cell lymphomas; James Essell
Panel Discussion (15 min)
- Repeat CAR-T following failure of a first CD19 CAR-T – does it work?: David Miklos
- Expanding CAR T-cells as a second-line therapy for LBCL – A paradigm shift?: Jason Westin
- Allogeneic CAR-T for NHL – fact or fantasy?: Tanya Siddiqi
- CAR T-cell therapy in the ‘real world’; Lazaros Lekakis
- Long-term outcomes following CAR-T cell therapy – what do we know so far? James Kochenderfer
Panel Discussion: CAR-T in the real-World Setting
Break
Session 7: Novel Therapies Part 2: BTK inhibitors
Chairs: Laurie Sehn & Tanya Siddiqi
- Ibrutinib combinations in younger lymphoma patient; Wyndham Wilson
- Zanubrutinib; Mazyar Shadman
- Acalabrutinib; Marek Trněný
- Pirtobrutinib; Nirav Shah
- BTK Degraders – NX-2127; Tanya Siddiqi
Panel Discussion
Lunch
Session 8: Bispecifics for NHL
Chairs: Martin Hutchings & Marion Subklewe
- CD20/CD3 bispecific antibodies – how to choose? Mazyar Shadman
- Glofitamab; Martin Hutchings
- Mosunetuzumab; Laurie Sehn
- Blinatumomab; Marion Subklewe
Roundtable Discussion
- Plamotamab; Krish Patel
- Odronextamab; Krish Patel
- TNB 486; Ranjit Nair
- Epcoritamab; Martin Hutchings
Roundtable Discussion
Closing remarks
John Gribben